851307-12-5

Basic information

• Product Name: Sitagliptin Defuoro IMpurity 3
• Synonyms: Sitagliptin Defuoro IMpurity 3;(3R)-3-[(tert-Butoxycarbonyl)amino]-4-(2,4-difluorophenyl)butanoic acid;(R)-3-(tert-butoxycarbonylaMino)-4-(2,4-difluorophenyl)butanoic acid;Sitagliptin iMpurity L;(R)-b-(Boc-amino)-2,4-difluorobenzenebutanoic acid;(R)-Sitagliptin Defluoro Impurity 3;Sitagliptin Defluoro Impurity 3;3-TERT-BUTOXYCARBONYLAMINO-4-(2,4-DIFLUORO-PHENYL)-BUTYRIC ACID
• CAS NO: 851307-12-5
• Molecular Formula: C₁₅H₁₉F₂NO₄
• Molecular Weight: 315.3124664
• Mol File: 851307-12-5.mol

Chemical Properties

• Boiling Point: 444.3±45.0 °C(Predicted)
• Appearance: /
• Density: 1.243±0.06 g/cm3(Predicted)
• Storage Temp.: 2-8°C
• PKA: 4.37±0.10(Predicted)
• CAS DataBase Reference: Sitagliptin Defuoro IMpurity 3(CAS DataBase Reference)
• NIST Chemistry Reference: Sitagliptin Defuoro IMpurity 3(851307-12-5)
• EPA Substance Registry System: Sitagliptin Defuoro IMpurity 3(851307-12-5)

Safety Data

• Hazardous Substances Data: 851307-12-5(Hazardous Substances Data)

Usage

Uses

Used in Pharmaceutical Industry:
Sitagliptin Defuoro IMpurity 3 is used as a critical component in the synthesis and quality control processes of Sitagliptin, a DPP-4 inhibitor. Its presence is essential for ensuring the purity, efficacy, and safety of the final pharmaceutical product intended for the treatment of type-2 diabetes.
Sitagliptin Defuoro IMpurity 3 is used as a reference material for analytical testing and method development in the pharmaceutical industry. This application is crucial for the accurate identification, quantification, and control of impurities in the final drug product, which is vital for maintaining the quality and consistency of Sitagliptin as a medication for diabetes management.
Additionally, Sitagliptin Defuoro IMpurity 3 may be utilized in research and development for the investigation of new therapeutic agents or improvements to existing treatments for type-2 diabetes and related metabolic disorders. Its role in these processes can contribute to advancements in pharmaceutical science and the development of more effective medications for patients.

Upstream product

• 81228-09-3 2,4-difluorophenylacetic acid 
• 141060-00-6 2-(2,4-difluorophenyl)acetyl chloride 
• 945261-73-4 C₁₉H₂₀F₂N₂O₃ 
• 942475-04-9 C₁₁H₁₀F₂O₃ 

Relevant articles and documents

Triazolopiperazine-amides as dipeptidyl peptidase IV inhibitors: Close analogs of JANUVIA (sitagliptin phosphate)

A series of β-aminoamides bearing triazolopiperazines has been prepared and evaluated as potent, selective, orally active dipeptidyl peptidase IV (DPP-4) inhibitors. Efforts at optimization of the β-aminoamide series, which ultimately led to the discovery

Discovery of potent and selective β-homophenylalanine based dipeptidyl peptidase IV inhibitors

Modification of in-house screening lead β-aminoacyl proline 8 gave an equipotent thiazolidide 9. Extensive SAR studies on the phenyl ring of 9 led to the discovery of a novel series of potent and selective DP-IV inhibitors. Introduction of a fluorine at the 2-position proved to be crucial for the potency of this series. The 2,5-difluoro (22q) and 2,4,5-trifluoro (22t) analogues were potent inhibitors of DP-IV (IC50 = 270, 119 nM, respectively).